Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Oncopeptides in connection with its rights issue
Mandate

Vinge has advised Oncopeptides in connection with its rights issue

March 14, 2024

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with issue proceeds of approximately SEK 300 million before deduction of transaction costs.

Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.

Vinge’s team consisted of Dain Hård Nevonen, William Kåge, Joel Magnusson, Annie Fällström and Maximilian Bengtsson.

Related

Vinge advises Advania on the acquisition of Cortex Consult A/S

 Vinge has advised Advania on the acquisition of Cortex Consult A/S, a Danish IT services company with more than 25 years of experience in managed IT services, cloud solutions and cybersecurity for customers across a range of industries.
August 18, 2026

Vinge advises Radonova Laboratories on the acquisition of the Norwegian company Skandinavisk Radoninvest

 Radonova Laboratories, a subsidiary of the Lagercrantz Group, has acquired all the shares in the Norwegian company Skandinavisk Radoninvest. Both companies operate in the field of radon measurement.
August 14, 2026

Vinge has advised KLAR Partners in connection with its divestment of Swoosh Group to Serwent

 Swoosh is a leading provider of inspection, maintenance, and services for underground infrastructure in Sweden, delivering sewer pipe inspection, cleaning, repair, and maintenance to municipalities, industrial operators, and property owners across 23 sites nationwide. Swoosh today employs approximately 450 people and generates revenues of nearly SEK 700 million.
August 13, 2026